Regeneron: PCSK9s Drowning In Paperwork
A common problem is plaguing both Regeneron Pharmaceuticals Inc. and Amgen Inc. – paperwork, specifically, the abundance of paperwork patients and physicians need to fill out to prescribe a PCSK9 inhibitor.
You may also be interested in...
ODYSSEY Outcomes data added to US label for Praluent; update includes claim for reduced cardiovascular incident risk and trial data indicating an all-cause mortality benefit.
Amgen’s PCSK9 blocker was cleared by FDA at a 420mg dose that can be administered once monthly via a hands-free device, offering a point of differentiation versus Sanofi/Regeneron’s Praluent.
Amgen and Sanofi/Regeneron will pay deeper discounts if patients taking Repatha and Praluent don’t experience similar levels of LDL-cholesterol lowering as was seen in clinical trials.